Abstract
Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models and three human trials. It affects multiple pathways to reduce apoptosis, neuroinflammation, infarct size, and vascular injury. The aim of this review is to discuss current evidence for minocycline from pre-clinical and early clinical trials and its potential role in neuroprotection in patients with acute ischemic stroke.
Keywords: Critical illness, ischemia, minocycline, neuroprotection, stroke, tetracycline.
Current Topics in Medicinal Chemistry
Title:Minocycline Repurposing in Critical Illness: Focus on Stroke
Volume: 13 Issue: 18
Author(s): T. Vivian Liao, Christy C. Forehand, David C. Hess and Susan C. Fagan
Affiliation:
Keywords: Critical illness, ischemia, minocycline, neuroprotection, stroke, tetracycline.
Abstract: Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models and three human trials. It affects multiple pathways to reduce apoptosis, neuroinflammation, infarct size, and vascular injury. The aim of this review is to discuss current evidence for minocycline from pre-clinical and early clinical trials and its potential role in neuroprotection in patients with acute ischemic stroke.
Export Options
About this article
Cite this article as:
Liao Vivian T., Forehand C. Christy, Hess C. David and Fagan C. Susan, Minocycline Repurposing in Critical Illness: Focus on Stroke, Current Topics in Medicinal Chemistry 2013; 13 (18) . https://dx.doi.org/10.2174/15680266113136660160
DOI https://dx.doi.org/10.2174/15680266113136660160 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design Lipoprotein-associated Phospholipase A2: A Potential Therapeutic Target for Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Advances in the Chemistry of Saccharins: From Synthetic Novelties Towards Biologically Active Compounds
Current Medicinal Chemistry The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Obesity and Cardioprotection
Current Medicinal Chemistry The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Quantification and Pharmacokinetics Study of Pedunculoside in Rats by Using UPLC-MS/MS
Current Pharmaceutical Analysis Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design